These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35894461)

  • 1. Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs).
    Oktavia L; Fuad AM; Senjaya SK; Yuliyawati Y
    Comb Chem High Throughput Screen; 2023; 26(6):1093-1107. PubMed ID: 35894461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
    Wang X; Xu L; Lao Y; Zhang H; Xu H
    Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
    Damare R; Engle K; Kumar G
    Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
    Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
    Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
    Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
    Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
    Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
    Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
    Liang Y; Zhang T; Zhang J
    Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities.
    Zubair T; Bandyopadhyay D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
    Sabbah DA; Hajjo R; Sweidan K
    Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological background of EGFR targeting.
    Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
    Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The story of EGFR: from signaling pathways to a potent anticancer target.
    Ramani S; Samant S; Manohar SM
    Future Med Chem; 2022 Sep; 14(17):1267-1288. PubMed ID: 35880513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibitors and autophagy in cancer treatment.
    Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY
    Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
    Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
    Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
    Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.